MOORE ALISON 4
4 · Allogene Therapeutics, Inc. · Filed Mar 24, 2023
Insider Transaction Report
Form 4
MOORE ALISON
Chief Technical Officer
Transactions
- Award
Stock Option (Right to buy)
2023-03-22+432,738→ 432,738 totalExercise: $5.04Exp: 2033-03-22→ Common Stock (432,738 underlying) - Award
Common Stock
2023-03-22+558,094→ 672,731 total
Footnotes (2)
- [F1]Includes 429,303 of performance RSUs which shall vest as follows: (1) 33% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 67% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period.
- [F2]25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.